GB910: Rheumatoid Arthritis
An Innovative Immune Therapy for Rheumatoid Arthritis,
an Autoimmune Disease Primarily Characterized by Chronic Synovial Inflammation
Therapeutic Strategy
GB910 is an innovative therapeutic agent that inhibits the activity of fibroblast-like synoviocytes (FLS), which are gaining attention as key regulatory cells in rheumatoid arthritis.
Rheumatoid arthritis is known to be driven by abnormally activated and hyperproliferative synoviocytes that interact with various immune cells, perpetuating inflammatory responses and exacerbating the disease. sGal-9, the core component of GB910, selectively binds to CD44, which is overexpressed on the surface of synoviocytes, effectively suppressing their hyperactivation.
While existing treatments have primarily focused on symptom relief, GB910 presents the potential for fundamental treatment of rheumatoid arthritis by directly controlling synoviocytes, the central regulators of chronic inflammation.
GB930: Lupus
An Innovative Immune Therapy for Lupus,
a Systemic Autoimmune Disease with High Risk of Multiple Organ Damage
Due to Its Extensive Invasion of Various Organs in the Body
Therapeutic Strategy
GB930 is an innovative dual-target therapeutic agent that simultaneously regulates the hyperactivation of pDCs and B cells, the core axis of lupus pathogenesis. It was developed to overcome the limited efficacy, temporary effects, and side effects of existing treatments.
sGal-9, the key component of GB930, selectively binds to CD44, which is overexpressed on the surface of pDCs and B cells in lupus patients, and inhibits TLR signal transduction, fundamentally blocking excessive activation of immune cells.
While existing treatments remain limited to symptomatic approaches or single-pathway inhibition, GB930 is expected to present a differentiated therapeutic strategy that can more precisely and comprehensively control the pathophysiology of lupus by simultaneously targeting pDCs and B cells.
